ELEV
Elevation Oncology Inc
stock NASDAQ

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. The company makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with its peers Elevation Oncology works towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at www.NRG1fusion.com.